ClinicalTrials.gg
CompletedNCT00813995Updated May 12, 2017Results posted

A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

A Phase 3 interventional study of Comparator: Sitagliptin phosphate and Comparator: Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
395
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
44th of 197
395 · median 102
Started
2008
with 22 others
Phase 3
74 of 198
none open now
Registered
58th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 44th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 74 in phase 3, and was the 58th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 78 years of age
  • Currently on metformin monotherapy

Exclusion criteria

Exclusion Criteria:

  • History of Type 1 diabetes mellitus or ketoacidosis
  • Currently on a weight loss program and not in the maintenance phase or has started on a weight loss medication within the last 8 weeks
  • Has undergone surgery requiring general anesthesia within the past 4 weeks or has planned major surgery
  • Currently participating in a study or has participated in a study with or without an compound or device within the past 12 weeks
  • History of active liver disease such as chronic active or C, cirrhosis or symptomatic gallbladder disease
  • positive
  • Pregnant, breast-feeding or planning to become pregnant during the study
  • User of recreational or illicit drugs or has a recent history (within the past year) of drug or alcohol abuse or dependence
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
395 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Drug: Comparator: Sitagliptin phosphate

  • Placebo comparator
    Placebo

    Drug: Comparator: Placebo

Interventions

  • All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.

    Also known as: GLUCOPHAGE®

  • DrugComparator: Placebo

    All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.

    Also known as: GLUCOPHAGE®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (A1C) at Week 24

    A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day

    A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.

    Time frame: Baseline and Week 24

  2. Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day

    A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.

    Time frame: Baseline and Week 24

  3. Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24

    Change from baseline at Week 24 is defined as Week 24 minus Week 0.

    Time frame: Baseline and Week 24

  4. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

    Change from baseline at Week 24 is defined as Week 24 minus Week 0.

    Time frame: Baseline and Week 24

07

Results

Posted Sep 13, 2011

Participant flow

Participant flow — Overall Study
MilestoneSitagliptinPlacebo
Started197198
Completed174182
Not completed2316
Withdrew: Clinical adverse event93
Withdrew: Laboratory adverse event02
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up42
Withdrew: Other reason22
Withdrew: Protocol violation32
Withdrew: Subject moved40
Withdrew: Withdrawal by subject05

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (A1C) at Week 24

A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent
Change From Baseline in Hemoglobin A1c (A1C) at Week 24
PercentSitagliptinPlacebo
Change From Baseline in Hemoglobin A1c (A1C) at Week 24-1.02 ± 0.99-0.14 ± 1.22
Statistical analysis
  • Sitagliptin vs Placebo · ANCOVA · p = <.001 (Pairwise comparison)
SecondaryChange From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day

A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent
Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day
PercentSitagliptinPlacebo
Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day-0.84 ± 1.09-0.01 ± 1.31
SecondaryChange From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day

A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent
Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day
PercentSitagliptinPlacebo
Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day-1.14 ± 0.88-0.21 ± 1.12
SecondaryChange From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24

Change from baseline at Week 24 is defined as Week 24 minus Week 0.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24
mg/dLSitagliptinPlacebo
Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24-43.4 ± 57.3-10.0 ± 60.0
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Change from baseline at Week 24 is defined as Week 24 minus Week 0.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
mg/dLSitagliptinPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24-20.3 ± 39.10.5 ± 40.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—7/197 (3.6%)10/197 (5.1%)
Placebo—5/198 (2.5%)13/198 (6.6%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventSitagliptinPlacebo
CEREBRAL INFARCTIONNervous system disorders2/1970/198
POST PROCEDURAL HAEMORRHAGEInjury, poisoning and procedural complications1/1970/198
DIABETES MELLITUSMetabolism and nutrition disorders1/1970/198
HYPERGLYCAEMIAMetabolism and nutrition disorders1/1970/198
LIP AND/OR ORAL CAVITY CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1970/198
IIIrd NERVE PARALYSISNervous system disorders1/1970/198
EPIGLOTTIC CYSTRespiratory, thoracic and mediastinal disorders1/1970/198
SPINAL CORD INJURY CERVICALInjury, poisoning and procedural complications0/1971/198
ALANINE AMINOTRANSFERASE INCREASEDInvestigations0/1971/198
TENOSYNOVITISMusculoskeletal and connective tissue disorders0/1971/198
Most frequent other events
Most frequent other events
EventSitagliptinPlacebo
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations10/19713/198

Baseline characteristics

Age, Continuous
Age, Continuous(years)SitagliptinPlaceboTotal
Mean54.1 ± 9.055.1 ± 9.854.6 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinPlaceboTotal
Female10590195
Male92108200
Region of Enrollment
Region of Enrollment(participants)SitagliptinPlaceboTotal
China197198395
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percent)SitagliptinPlaceboTotal
Mean8.5 ± 0.98.5 ± 0.98.5 ± 0.9
2-hour Post-meal Glucose
2-hour Post-meal Glucose(mg/dL)SitagliptinPlaceboTotal
Mean258.0 ± 58.0258.7 ± 63.2258.3 ± 60.6
Fasting Plasma Glucose
Fasting Plasma Glucose(mg/dL)SitagliptinPlaceboTotal
Mean173.4 ± 39.3173.9 ± 40.0173.7 ± 39.6
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Yang W, Guan Y, Shentu Y, Li Z, Johnson-Levonas AO, Engel SS, Kaufman KD, Goldstein BJ, Alba M. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes. 2012 Sep;4(3):227-37. doi: 10.1111/j.1753-0407.2012.00213.x. PubMed 22672586 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2008 to primary completion in Aug 2010, 20 months.

Results were first posted in Sep 2011, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2008
First posted
Dec 23, 2008
StartActual
Dec 9, 2008
Primary completionActual
Aug 9, 2010
CompletionActual
Aug 9, 2010
Results first posted
Sep 13, 2011
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00813995
Responsible party
Sponsor
First posted
Dec 23, 2008
Start date
Dec 9, 2008
Primary completion
Aug 9, 2010
Completion
Aug 9, 2010
Results posted
Sep 13, 2011
Last update
May 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion